RET Fusion Lung Cancer: The Complete Patient Guide

You have just learned that you have RET fusion lung cancer. Or that someone you love has received this diagnosis.

I know what you are going through. I have been there.

The first reaction is to feel like the world has stopped. Then comes the need to do something – anything – immediately. But here is what I have learned: the most important thing you can do right now is understand what you have, what options exist, and how to avoid the mistakes that can cost you.

This guide gives you everything you need to know – from diagnosis to treatment, from side effects to emergencies, from what lies ahead to how you live day to day with this diagnosis. It is the map I wish I had.

The good news, before anything else: Your cancer has an approved, targeted treatment that works. You are not stuck with generic chemotherapy. Read on.

What you have – understanding the diagnosis

You have a rare subtype of non-small cell lung cancer (NSCLC) driven by a RET gene fusion. Two genes in your tumor cells have joined together, creating an abnormal protein that tells cells to grow without stopping. The good news: this fusion is targetable – there is a precision drug designed specifically for it.

What RET fusion means

Your cancer cells carry a specific genetic alteration: the RET gene has fused with another gene (most commonly KIF5B or CCDC6, though other partners exist). This fusion creates a signaling protein “stuck on” that drives cancer growth. Selpercatinib (Retevmo) directly blocks this abnormal RET protein.

The fusion partner matters:

Ask your doctor: “What RET fusion partner do I have?” The answer influences prognosis and treatment decisions if resistance develops.

How the diagnosis was confirmed

The RET fusion was identified through molecular testing – a genetic analysis of your tumor. Selpercatinib must be given only to patients with confirmed RET fusions.

Who gets RET fusion lung cancer

This type of cancer has a distinct patient profile:

• Age: Younger patients (median 55-62 years)
• Smoking: 55-70% are never-smokers or light smokers
• Sex: More common in women (60-70%)
• Histology: 99%+ are adenocarcinomas
• Important: RET fusions occur alone – they do not usually coexist with EGFR, ALK, or ROS1

Your cancer is NOT caused by smoking. It is a spontaneous genetic accident in the tumor cells, not in your inherited genes. If you are at the beginning of your journey, also read the complete oncology diagnosis guide – it covers the correct order of steps, from PET-CT to molecular testing.

Prognosis: the real numbers

Without RET-targeted therapy (older data): Median survival of 8-12 months with standard chemotherapy.

With Selpercatinib (current treatment):

• Overall response rate (ORR): 84% in patients who receive it as first-line treatment
• Progression-free survival (PFS): 24.8 months – most patients remained stable on treatment for nearly two years
• Disease control rate: 88%
• Overall survival (OS): Not yet reached after 3.5+ years in first-line treated patients

Brain metastases are common: 46% of RET fusion patients develop brain tumors during their lifetime. Regular brain MRI is essential.

The number that truly matters: Your individual prognosis depends on stage, fusion partner, co-mutations (such as TP53), and how your specific tumor responds to Selpercatinib. Ask your oncologist for YOUR NUMBERS.

Co-mutations to check for

Ask your doctor: “Does my tumor have co-mutations besides RET? Especially TP53 or PIK3CA?”

The best treatment right now

Selpercatinib (Retevmo) – the standard first-line treatment

Selpercatinib is the preferred selective RET inhibitor for RET fusion lung cancer. Here is why:

• Doubles PFS compared to chemotherapy + pembrolizumab: 24.8 months vs. 11.2 months
• Superior response rate: 84% tumor reduction in first-line treated patients
• Brain penetration: 91% intracranial response rate in patients with brain metastases at baseline
• Selective for RET – fewer side effects than older multi-kinase inhibitors

Why immunotherapy does NOT work in RET-fused cancer

Why? RET fusion-positive tumors have “cold” immune microenvironments with low PD-L1 expression. Immunotherapy targets the PD-1/PD-L1 axis – your cancer does not depend on this checkpoint.

LIBRETTO-431 explicitly showed: Pembrolizumab added to chemotherapy did not improve outcomes compared to chemotherapy alone in RET+ patients, and both were inferior to Selpercatinib.

Selpercatinib vs. Pralsetinib (Gavreto)

Important for Romania and the EU: Pralsetinib (Gavreto) was withdrawn from the EU in October 2024 – not for safety reasons, but through a commercial decision by the manufacturer. Selpercatinib is the only targeted RET inhibitor available in Europe.

What NOT to do – mistakes that can cost you

If you are on Selpercatinib, the decisions you make outside the clinic matter just as much as those inside it. Some mistakes are easy to make – a glass of juice, a vitamin, a supplement recommended by a neighbor. All of them can cost you.

Read this section carefully. Print it. Show it to your family.

MISTAKE 1: Grapefruit juice

What happens: Grapefruit inhibits CYP3A4, the liver enzyme that breaks down Selpercatinib. When CYP3A4 is blocked, Selpercatinib accumulates in the blood at dangerously high concentrations. A single glass of grapefruit juice is enough to cause harm.

Instead: Completely eliminate grapefruit, grapefruit juice, and products containing grapefruit for the entire duration of treatment. Oranges, apples, and lemons are safe.

MISTAKE 2: St. John’s Wort

What happens: St. John’s Wort does the opposite of grapefruit – it speeds up CYP3A4, dramatically reducing the amount of drug in your blood. Less drug = treatment stops working. The tumor may progress silently.

Instead: Do NOT take St. John’s Wort in any form during treatment. If you have depression or fatigue, tell your oncologist – there are options that do not interact with your treatment.

MISTAKE 3: Antibiotics without telling your oncologist

What happens: Clarithromycin (Biaxin/Klacid) is a strong CYP3A4 inhibitor. Like grapefruit, it can make your Selpercatinib level rise dangerously in the blood.

Instead: Tell every doctor who prescribes you anything: “I am on Selpercatinib – a CYP3A4 substrate.” If you are prescribed clarithromycin, ask for alternatives (azithromycin, amoxicillin) – discuss with your oncologist first.

MISTAKE 4: High-dose antioxidant supplements

What happens: Research shows that antioxidant supplements (vitamin A, C, E, coenzyme Q10) taken during treatment can protect cancer cells from the effects of therapy, reducing treatment effectiveness.

Instead: Get nutrients from food, not from megadose pills. Bring a complete list of every supplement to every appointment. “Natural” does not mean safe during cancer treatment.

MISTAKE 5: Stopping Selpercatinib because you feel better

What happens: RET inhibitors are not cures – they continuously suppress tumor growth. Stopping allows residual cancer cells to resume proliferating. Underdosing can allow resistant clones to emerge.

Instead: Side effects, even severe ones, usually have manageable solutions. If they become unbearable, call your oncologist the same day – do not stop treatment on your own.

MISTAKE 6: Replacing treatment with alternative medicine

What happens: RET fusion-positive lung cancer has a specific, targetable molecular driver. No alternative remedy targets RET fusions. Delaying effective therapy allows cancer to progress to a point where subsequent treatment becomes less effective or impossible.

Instead: Complementary approaches (nutrition, exercise) can support treatment – they do not replace it. If you are considering cannabis-based products, tell your oncologist – some can interact with CYP3A4 pathways.

MISTAKE 7: Ignoring new respiratory symptoms

What happens: Selpercatinib can cause interstitial pneumonitis (severe lung inflammation) – a serious, potentially life-threatening complication documented in RET+ lung cancer patients.

Instead: Call your oncology team immediately if you experience: new or worsening shortness of breath, persistent dry cough, chest discomfort, fever with respiratory symptoms. Do NOT wait for your next appointment.

MISTAKE 8: Assuming your psychiatrist or GP knows the interactions

What happens: Selpercatinib is a moderate CYP3A4 inhibitor – it can affect the metabolism of other medications (including psychiatric ones). The interaction goes both ways.

Instead: Give every doctor, every dentist, and every pharmacist the complete list of your oncology medications. Do not assume specialists communicate with each other – they often do not.

Quick reference: substances to avoid on Selpercatinib

How to take your treatment correctly

Selpercatinib (Retevmo) dosing

Take the pills at the same times every day. Set phone alarms – consistency prevents drug level drops.

Critical rules for stomach acid and food

Selpercatinib has pH-dependent solubility: it dissolves well in acid and becomes practically insoluble at neutral pH. Anything that raises stomach pH reduces how much drug reaches the blood.

Water: Take Selpercatinib with ~200 ml (a small cup) of water. Avoid drinking a full glass (over 400 ml) at the same time – large amounts of water dilute stomach acid.

If you missed a dose

• Remembered within a few hours? Take it immediately, then resume your normal schedule
• It is nearly time for the next dose? Skip the missed dose. Do NOT take a double dose
• Not sure? Call your pharmacist or oncology nurse

If you vomited after a dose

Do NOT retake the dose. Your stomach has already absorbed most of it. Resume your normal schedule at the next planned time.

Side effects – real probabilities

This section shows you what actually happens to patients on Selpercatinib. Real numbers, not vague phrases.

The honest picture: In a real-world study of 243 patients, 86% had at least one adverse event and 48% had a severe one (Grade 3+). But this does NOT mean treatment is intolerable – most patients report stable or improved quality of life.

What will PROBABLY happen (over 50% of patients)

Common and manageable

Rarer but DANGEROUS – attention saves lives here

Newly identified risks (real-world data, December 2024)

Side effects not previously on the label, found through pharmacovigilance and real-world studies:

• Dysphagia – difficulty swallowing. Report to oncologist if new or worsening
• Pericardial effusion – fluid around the heart (chest pressure, shortness of breath when lying down). Baseline echocardiogram recommended, repeat every 6 months or at symptom onset
• Hemiparesis – weakness on one side of the body (stroke-like). Requires urgent brain MRI to differentiate from brain metastases
• Intestinal lymphangiectasia – protein-losing enteropathy found in up to 29% of patients (TTLC 2026, MSKCC). Causes chronic diarrhea, malabsorption, and low albumin. Manageable with low-fat MCT diet and dose adjustment. Monitor albumin at every blood draw

Thyroid function – the forgotten check

Selpercatinib inhibits DIO2, the enzyme that converts T4 (inactive thyroid hormone) to T3 (the active form). Approximately 13% of patients develop clinical hypothyroidism – which causes fatigue, weight gain, and fluid retention that can be confused with other side effects.

The fix is simple: levothyroxine, a cheap medication with zero CYP3A4 interaction. But it only works if the problem is detected.

Ask your oncologist to add TSH + free T4 to every blood draw. If TSH rises above 4.5 or free T4 drops below normal, levothyroxine should be started.

How side effects evolve over time

The side effect profile of selpercatinib changes significantly over 6-24 months. What bothers you at month 2 is not the same as what bothers you at month 18:

This is important to know because:

• It is manageable – only 2% of patients discontinue selpercatinib due to side effects
• Preparation helps – compression stockings, loperamide supply, MCT diet knowledge, thyroid monitoring
• Dose adjustment works – late side effects respond to dose reduction without necessarily losing efficacy

Drug and food interactions

Selpercatinib is primarily metabolized by CYP3A4 and CYP2C8 enzymes in the liver. Think of these enzymes as “chemical scissors.” If something blocks the scissors, the drug level rises. If something sharpens them, the drug level drops.

Substances that INCREASE Selpercatinib levels (DANGER)

If you MUST take a strong CYP3A4 inhibitor, your Selpercatinib dose may be reduced to 80 mg twice daily, with more frequent cardiac monitoring.

Substances that REDUCE effectiveness (treatment stops working)

Other foods and substances that may affect Selpercatinib

Interaction checklist – print and bring to every pharmacy

• Tell the pharmacist: “I am on Selpercatinib (RETEVMO) for lung cancer”
• Ask: “Does this new medication inhibit or induce CYP3A4?”
• Ask: “Does it interact with Selpercatinib?”
• Ask: “Can it affect heart rhythm or blood pressure?”

What monitoring you need

Monitoring is not optional – it is an essential part of treatment that keeps you alive and catches problems early.

Baseline tests BEFORE the first dose

Schedule: what tests, when

Brain MRI – do NOT wait for headaches

46% of RET fusion patients develop brain metastases. Many are asymptomatic initially.

If your doctor says “we will scan if you have symptoms,” push back – surveillance scanning is the standard of care for RET fusion lung cancer.

How to interpret liver tests

When to go to the emergency room – NOW

PRINT THIS PAGE. PUT IT ON YOUR FRIDGE. CARRY IT IN YOUR WALLET. GIVE A COPY TO YOUR PARTNER/FAMILY.

EMERGENCY CHECKLIST – Go to the emergency room if you have any of these:

What to bring to the emergency room – every time

Do NOT take your next dose if you are in the ER for any of the situations above.

Serious but NOT immediately life-threatening – call your oncologist TODAY

• Blood pressure above 140/90 mmHg on two separate readings
• Unexplained weight gain of over 2 kg in 3 days (possible edema)
• Persistent nausea and vomiting preventing you from taking Selpercatinib
• New hyperglycemia symptoms (extreme thirst, frequent urination, blurred vision)
• Any new neurological symptoms

Where it spreads and what to do

Brain metastases – complication number 1

Nearly 50% of RET fusion patients will develop brain metastases during their lifetime. This is not a rare event – it is the most common complication.

Does Selpercatinib work in the brain? Yes. 82% brain response rate in the LIBRETTO-431 trial. Selpercatinib can also prevent the development of new brain metastases.

If brain metastases develop despite Selpercatinib:

Bone metastases

Bone is a common site of metastasis. If you have unexplained bone pain, report it immediately – do not assume it is arthritis or aging.

• Bone pain: Radiation to the painful site + pain medication
• Fracture risk: Denosumab (Xgeva) or bisphosphonates to strengthen the bone
• Spinal metastases: If you develop back pain + weakness/numbness in the legs, go to the ER immediately – risk of spinal cord compression

Denosumab (Xgeva) protocol for bone metastases

If you have bone metastases, Xgeva (denosumab) is recommended to prevent complications (fractures, spinal cord compression).

• Administration: 120 mg subcutaneous injection every 28 days
• Vitamin D: Minimum 400 IU daily
• Calcium: Minimum 600 mg daily – preferably calcium citrate (better absorption)
• CRITICAL: Take calcium supplements at least 2 hours BEFORE OR 2 hours AFTER Selpercatinib
• Practical example: Selpercatinib at 8:00 AM and 8:00 PM. Calcium + Vitamin D at noon
• Dental warning: Tell your dentist you are on Xgeva before any dental procedure

Oligometastatic management – the key concept

If you have a limited number of metastases (1-5 sites), the most effective strategy may be local treatment of resistant lesions (radiation, ablation) while continuing Selpercatinib – not changing the entire treatment plan.

The logic: if most of your cancer responds to Selpercatinib but 1-2 sites are growing, those sites may have local resistance. Destroying them eliminates the resistant cells while Selpercatinib continues to control the rest.

Ask your oncologist: “Do I have oligometastatic disease? Would SBRT or ablation be appropriate for some lesions, while continuing Selpercatinib?”

When treatment stops working

The difficult truth: virtually every patient on Selpercatinib will eventually develop resistance. The question is not “if” – but “when,” “how,” and “what do you do next.” You need a plan BEFORE you need it.

Two families of resistance

What to request at progression

Do not accept “the cancer is growing” as a complete answer. Demand to know WHY.

1. Liquid biopsy (ctDNA) – a blood test that detects resistance mutations months before scans show tumor growth
2. Tissue re-biopsy – if liquid biopsy is negative but progression is clear
3. Full NGS – mandatory with every re-biopsy

Your resistance strategy: three levels

LEVEL 1 – Options available NOW:

LEVEL 2 – Next-generation RET inhibitors (in clinical trials NOW):

LEVEL 3 – Targeted combinations (based on YOUR resistance mechanism):

Expert centers that think ahead

Ask your oncologist: “Can you refer me to one of the centers above for a second opinion or trial enrollment?”

What lies ahead – pipeline and clinical trials

Frontier technologies (2-5+ years away, but real science)

Histotripsy – Focused ultrasound waves destroy tumors without surgery, without radiation. FDA-approved for liver tumors (2023). Relevant if you develop liver metastases.

LungVax vaccine (Oxford/UCL) – The first preventive lung cancer vaccine. Trains the immune system to recognize “alarm signal” proteins on abnormal lung cells. Phase I from summer 2026. Relevant if you achieve remission and worry about recurrence.

PROTACs – Instead of blocking the RET protein (as Selpercatinib does), they destroy the RET protein completely through the cell’s own disposal system. You cannot develop binding-site resistance if the entire protein is destroyed. 3-5 years from patients.

ANKTIVA + Keytruda – IL-15 grows new T cells and NK cells; Keytruda unblocks them. Conditional EU authorization (February 2026). Phase 3 trial for NSCLC (ResQ201A) currently enrolling.

mRNA cancer vaccines – BNT116 (BioNTech): FDA filing 2025 for NSCLC. Over 120 mRNA oncology vaccine clinical trials underway.

How to find and enroll in a clinical trial

• ClinicalTrials.gov – search “RET fusion NSCLC” for open trials
• LUNGevity Foundation – LungMATCH navigator
• The Happy Lungs Project (happylungsproject.org) – tracks RET-specific trials
• RETpositive.org – clinical trial database and community
• Compassionate / expanded access: ask your oncologist if LOXO-260 or other experimental drugs are available outside of trials
• In Romania/EU: cross-border enrollment in an EU clinical trial is possible

Day-to-day life on Selpercatinib

Realistic treatment timeline

Weeks 1-2: Nausea, appetite loss, fatigue, dry mouth. Establish your dosing routine. Highest risk of tumor lysis syndrome.

Months 1-3: Side effects declare themselves. Fatigue may deepen. Blood pressure may start to rise. Highest risk of hepatotoxicity – blood tests every 2 weeks. 31% of patients need a dose reduction.

Months 3-12: If you have tolerated it this far, acute risks decrease (but do not disappear). The first scans will likely show response. Exercise and nutrition become critical.

Year 1-2: Most patients still respond (median PFS ~24.8 months). Start discussing with your doctor: what is the plan if resistance develops?

Year 2+: Statistically, roughly half of patients will see progression. Some continue to respond much longer.

Exercise – the most supported non-drug intervention

What works: Aerobic + resistance training combined.

How often: 3 times per week. Programs under 12 weeks show the strongest fatigue reduction.

Start with: Walking. Even 10-15 minutes. Increase gradually.

The trap: Fatigue makes you want to rest. Resting makes fatigue worse. Movement breaks the cycle.

Eating during treatment

Small, frequent meals – 5-6 per day instead of 3.

Protein-rich foods – protect against muscle wasting.

Fruits and vegetables: 5-6 servings per day. Antioxidants from food are OK; antioxidant supplements are NOT.

When food tastes wrong: Cold foods (less smell), experiment with seasonings.

Request a referral to an oncology dietitian – this is treatment support, not wellness advice.

Mental health

Anxiety, depression, and adjustment disorders are common and predictable responses to diagnosis and ongoing treatment. This is not weakness.

Seek psychological support proactively – do not wait until you are in crisis:

• Counseling or therapy (individual, group, or couples)
• Support groups for lung cancer patients
• Financial counseling if treatment costs are a burden

Fertility

Selpercatinib is teratogenic (causes birth defects). Women must use effective contraception during treatment and for 1 week after stopping.

If you want children, discuss fertility preservation BEFORE continuing treatment. Freezing eggs or sperm before starting is an option.

Surgery and travel

• Stop Selpercatinib at least 7 days before ANY surgery, including dental
• Travel: Carry Selpercatinib in the original bottles in your carry-on luggage. Carry a letter from your oncologist confirming the prescription

Treatment access

Romania – FREE, but requires a legal procedure for first-line access

Context: Selpercatinib was initially approved as a second-line treatment (after chemotherapy failure). In 2022 (FDA) and 2023 (EMA), it was updated to first-line treatment based on the LIBRETTO-431 results. Both ESMO and NCCN now recommend Selpercatinib as Category 1 first-line monotherapy.

The problem in Romania: CNAS (the national health insurance authority) has not updated its reimbursement guidelines. Selpercatinib is covered through standard channels only as a second-line treatment. Romanian patients are forced to undergo inferior chemotherapy first – contradicting international guidelines – unless they use the legal pathway below.

How to get free access to Selpercatinib in Romania

1. Contact a lawyer experienced in medical law (a patient advocacy organization can recommend one)
2. The lawyer files an “Ordonanta Presedintiala” (emergency court order) against CNAS
3. The court file must include:
   • A letter from your oncologist specifying Selpercatinib (Retevmo) as the recommended first-line treatment
   • ESMO Clinical Practice Guidelines for metastatic NSCLC
   • EMA Marketing Authorization for Retevmo
4. Timeline: The court typically grants the order within 3-4 weeks
5. Once approved, CNAS covers the full cost – treatment is free for the patient

After the court approves your request

1. Choose a pharmacy where you will pick up the medication from now on
2. Your oncologist must write simple prescriptions (like antibiotic prescriptions) – NOT electronic prescriptions with QR codes. QR prescriptions go through the standard CNAS system that does not cover first-line Selpercatinib. A simple prescription, backed by the court order, bypasses this limitation
3. Contact the pharmacy at least 1 week before picking up the medication – Selpercatinib is not routinely stocked and the pharmacy needs time to order it
4. Keep copies of the court order with you at all times. The pharmacy will need to see it

Be prepared: Even with the court order and full coverage, access can be unpredictable. The pharmacy may have supply delays, the prescription format may cause confusion for staff unfamiliar with the procedure. Patience and persistence are unfortunately part of treatment in Romania.

Access in other European countries

Manufacturer assistance programs (Eli Lilly)

If you are uninsured or have high co-pays:

• Contact: 1-844-RETEVMO (US) or the Eli Lilly support line in your country
• Offers: compassionate access, co-pay assistance, expanded access programs
• Processing in 2-3 weeks

You are not alone

RET-specific communities

Support for caregivers

Your family members are affected too. Do not ask them to navigate this alone.

• LUNGevity Caregiver Support Groups – online forums for families
• CancerCare Support Groups – free support group for caregivers
• My Cancer Circle – free online tool for organizing the care network
• American Lung Association Survivor Network – peer support and shared experiences